细胞外囊泡作为新型疫苗接种途径的抗原载体。
Extracellular vesicles as antigen carriers for novel vaccination avenues.
机构信息
Helmholtz Institute for Pharmaceutical Research Saarland, Biogenic Nanotherapeutics Group, Campus E8.1, 66123 Saarbrücken, Germany; Department of Pharmacy, Saarland University, Campus E8.1, 66123 Saarbrücken, Germany; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, 11566 Cairo, Egypt.
Helmholtz Institute for Pharmaceutical Research Saarland, Department of Drug Delivery, Campus E8.1, 66123 Saarbrücken, Germany; Department of Pharmacy, Saarland University, Campus E8.1, 66123 Saarbrücken, Germany.
出版信息
Adv Drug Deliv Rev. 2021 Jun;173:164-180. doi: 10.1016/j.addr.2021.03.016. Epub 2021 Mar 26.
Antigen delivery has always been a challenge in scientific practice of vaccine formulation. Yet, mammalian extracellular vesicles (EVs) or bacterial membrane vesicles (MVs) provide an innovative avenue for safe and effective delivery of antigenic material. They include intrinsically loaded antigens from EV-secreting cells or extrinsically loaded antigens onto pre-formed vesicles. Interestingly, many studies shed light on potential novel anti-cancer vaccination immunotherapy for therapeutic applications from mammalian cell host-derived EVs, as well as conventional vaccination for prophylactic applications using bacterial cell-derived MVs against infectious diseases. Here, we discuss the rationale, status quo and potential for both vaccine applications using EVs.
抗原递呈一直是疫苗制剂科学实践中的一个挑战。然而，哺乳动物细胞外囊泡 (EVs) 或细菌膜囊泡 (MVs) 为安全有效地递呈抗原物质提供了一条创新途径。它们包括 EV 分泌细胞中内在负载的抗原，或预先形成的囊泡上的外在负载的抗原。有趣的是，许多研究揭示了哺乳动物细胞来源的 EV 用于治疗性应用的新型抗癌疫苗免疫疗法的潜力，以及使用细菌细胞来源的 MVs 进行预防性应用的常规疫苗接种，以预防传染病。在这里，我们讨论了使用 EV 进行这两种疫苗应用的原理、现状和潜力。
Zotero 插件